ELEVATED IMMUNOREACTIVE ENDOTHELIN LEVELS IN PATIENTS WITH PHEOCHROMOCYTOMA

被引:27
作者
OISHI, S
SASAKI, M
SATO, T
机构
[1] Third Department of Internal Medicine, Kumamoto University School of Medicine, Kumamoto
关键词
ENDOTHELIN; CATECHOLAMINE; HYPERTENSION; PHEOCHROMOCYTOMA;
D O I
10.1093/ajh/7.8.717
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Plasma immunoreactive endothelin-1 (ET-1) concentrations were measured in 44 patients with pheochromocytoma, 31 patients with essential hypertension, and 20 healthy control subjects. Plasma ET-1 concentrations in patients with pheochromocytoma were 18.2 +/- 3.2 fmol/mL (mean +/- SEM), which was significantly higher than those of essential hypertension and healthy Control subjects (7.3 +/- 0.4, 7.1 +/- 0.4 fmol/mL, respectively, P < .01). Plasma ET-1 concentrations in patients with essential hypertension and control subjects were similar. In patients with pheochromocytoma, hypertensive group had higher ET-1 than normotensive group (23.0 +/-: 5.5 v 12.4 +/- 2.2 fmol/mL), but the difference was not significant. In 17 patients with pheochromocytoma, the elevated plasma ET-1 concentrations (17.4 +/- 4.7 fmol/mL,) returned to normal levels (7.9 +/- 0.6 fmol/mL, P < .05) after surgical resection of the tumor. ET-1 contents in the 26 tumor tissues (1.40 +/- 0.29 pmol/g) were higher than those in 7 normal adrenal medullas (0.44 +/- 0.12 pmol/g). Systolic, diastolic, and mean blood pressures were better correlated with plasma norepinephrine than ET-1 in patients with pheochromocytoma. These data indicate that pheochromocytoma might produce and secrete excessive amounts of ET-1. The hypertension in patients with pheochromocytoma is mainly catecholamine-dependent, but may be secondarily ET-1-dependent.
引用
收藏
页码:717 / 722
页数:6
相关论文
共 27 条
[1]  
Yanagisawa M., Kurihara H., Kimura S., Et al., A novel potent vasoconstrictor peptide produced by vascular endothelial cells, Nature, 332, pp. 411-415, (1988)
[2]  
Mortenson L.H., Pawloski C.M., Kanagy N.L., Et al., Chronic hypertension produced by infusion of endo- thelin in rats, Hypertension, 15, pp. 317-320, (1990)
[3]  
Miller W.L., Redfield M.M., Burnett J.C., Integrated cardiac, renal, and endocrine actions of endothelin, J Clin Invest, 83, pp. 317-320, (1989)
[4]  
Rakugi H., Nakamura M., Saito H., Et al., Endothelin inhibits renin release from isolated rat glomeruli, Bio-Chem Biophys Res Commun, 155, pp. 1244-1247, (1988)
[5]  
Morishita R., Higaki J., Ogihara T., Endothelin stimulates aldosterone biosynthesis by dispersed rabbit adrenocapsular cells, Biochem Biophys Res Commun, 160, pp. 628-632, (1989)
[6]  
Marriott, Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells, J Cardiovasc Pharmacol, 13, pp. S223-S224, (1989)
[7]  
Nakamoto H., Suzuki H., Murakami M., Et al., Effects of endothelin on systemic and renal hemodynamics and neuroendocrine hormones in conscious dogs, Clin Sci, 77, pp. 567-572, (1989)
[8]  
Ishikawa T., Yanagisawa M., Kimura S., Et al., Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria, Am J Physiol, 255, pp. H970-H973, (1988)
[9]  
Saito Y., Nakao K., Mukoyama M., Et al., Increased plasma endothelin level in patients with essential hypertension, N Engl J Med, 322, (1990)
[10]  
Kohno M., Yasunari K., Murakawa K., Et al., Plasma immunoreactive endothelin in essential hypertension, Am J Med, 88, pp. 614-618, (1990)